A randomized, double-blind, placebo-controlled multi-center study to evaluate the safety and efficacy of Fentanyl sublingual spray (Fentanyl SL spray) for the treatment of breakthrough cancer pain.

Trial Profile

A randomized, double-blind, placebo-controlled multi-center study to evaluate the safety and efficacy of Fentanyl sublingual spray (Fentanyl SL spray) for the treatment of breakthrough cancer pain.

Completed
Phase of Trial: Phase III

Latest Information Update: 02 May 2014

At a glance

  • Drugs Fentanyl (Primary)
  • Indications Cancer pain
  • Focus Registrational; Therapeutic Use
  • Sponsors INSYS Therapeutics, Inc
  • Most Recent Events

    • 19 May 2012 Results presented at the 31st Annual Scientific Meeting of the American Pain Society.
    • 19 May 2010 Primary endpoint identified as pain relief as reported by ClinicalTrials.gov.
    • 19 May 2010 Primary endpoint identified as pain relief as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top